Прамипексол пролонгированного действия – новое терапевтическое направление в лечении болезни Паркинсона (обзор литературы)

1. Нодель М.Р., Артемьев Д.В., Яхно Н.Н. Эффективность дофаминового агониста мирапекса при болезни Паркинсона. Неврологический журнал. 1999; 6 (4): 45–9.
2. Федорова Н.В., Смоленцева И.Г., Левин О.С. Применение агонистов дофаминовых рецепторов при болезни Паркинсона. Рус. мед. журн. 2000; 15–16 (8): 643–7.
3. Moller C, Oertel WH. Pramipexole in the treatment of Parkinson's disease: new developments. Expert Review of Neurotherapeutics 2005; 5 (5): 581–6.
4. Holloway RG, Shoulson I, Fahn S et al. Pramipexole vs levodopa as initial treatment for Parkinson’s disease: a 4-year randomized controlled trail. Arch Neurol 2004; 61: 1044–53.
5. Barone P, Poewe W, Albrecht S et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomized, double-blind, placebo-controlled trail. Lancet Neurol 2010; 9: 573–80.
6. Navan P, Findley LJ, Pearce RG et al. A randomly assigned double-blind cross-over study examining the relative anti-parkinsonian tremor effects of pramipexole and pergolide. Eur J Neurol 2005; 12 (1):1–8.
7. Bennett JP, Piercey MF. Pramipexole – a new dopamine agonist for the treatment of Parkinson’s disease. J Neurol Sci 1999; 163: 25–31.
8. Schapira AH, Albrecht S, Barone P et al. Rationale for delayed-start study of pramipexole in Parkinson’s disease the PROUD study. Mov Disord 2010; 25: 1627–32.
9. Claudrine M, Chwieduk, Monique P Curran. Pramipexole extended-release in Parkinson’s disease. CNS Drugs 2010; 24 (4): 327–36.
10. Poewe WH, Barone P, Hauser RA et al. Pramipexole extended-release is effective in early Parkinson’s disease. Mov Disord 2009; 24 (Suppl. 1): 273.
11. Salin L, Hauser R, Koester J. Double-blind evaluation of maintenance of efficacy of pramipexole extended-release in early Parkinson's disease. Proceedings of the 61st Annual Meeting of the American Academy of Neurology. USA 2009. Abs. P06.150. Neurology 72: 11.
12. Hauser R, Salin L, Koester J. Double-blind evolution of pramipexole extended-release (ER) in early Parkinson's disease. Neurology 2009; 11 (72, Suppl. 3): A412–3.
13. Schapira AH, Barone P, Hauser RA et al. Efficacy and safety of pramipexole extended-release for advanced Parkinson's disease. Mov Disord 2009; 24 (Suppl. 1): 277–8.
14. Rascol O, Barone P, Debieuvre C et al. Easy switching from immediate- to extended-release pramipexole in early Parkinson's disease the same daily dosage. Mov Disord 2009; 24 (Suppl. 1): 362.
15. Rascol O, Barone P, Debiuvre D et al. Overnight switching from immediate- to extended-release (ER) in early Parkinson's disease. Neurology 2009; 11 (72): А320.
16. Mizuno Y, Yamamoto M, Kuno S et al. Efficacy of pramipexole extended release (ER) and switching from immediate release (IR) ER in Japanese advanced Parkinsons disease (PD) patients. Proceedings of the 18th WFN World Congress on Parkinson’s Disease and Related Disordes. Miami Beach. USA 2009; Poster 2.192.
17. Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson’s disease. Mov Disord 2005; 20: 1502–7.
18. Grosset D, Antonini A, Caneci M et al. Adherence to antiparkinson medication in a multicenter European study. Mov Disord 2009; 24: 826–32.
19. Рarkinson Study Group. A randomized controlled trial comparing Pramipexole with Levodopa in early Parkinson’s disease: design and methods of the CALM-PD study. J Clin Neuropharmakol 2000; 1 (23): 34–44.

Н.В.Федорова

Кафедра неврологии РМАПО, Центр экстрапирамидных заболеваний, Москва